The main purpose of this study is to evaluate the safety and tolerability of LY3041658 in healthy participants. The study will measure how the body absorbs, breaks down and gets rid of LY3041658.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
16
Administered SC
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Number of Participants With incidence and severity of Injection Site Reaction (ISR)
Number of Participants With incidence and severity of ISR
Time frame: Baseline up to Day 15
Visual Analog Scale (VAS) Score for Injection Site Pain
VAS Score for Injection Site Pain
Time frame: Baseline up to Day 1
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3041658
PK: Cmax of LY3041658
Time frame: Predose up to day 85 postdose
PK: Area Under the Concentration Versus Time Curve (AUC) from time 0 to infinity of LY3041658
PK: AUC(0-inf) of LY3041658
Time frame: Predose up to day 85 postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.